Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis.

ABSTRACT:

Objective

The effect of the shared epitope (SE) and valine at position 11 (Val11) of HLA-DRB1 on the activation of CD4⁺ T cells is expected to be diminished by abatacept, a costimulation blocker. However, published evidence on the value of genetic stratification for abatacept treatment is conflicting. We aimed to compare the difference in effectiveness of abatacept and adalimumab in patients carrying the SE (or Val11).

Methods

The Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate is a nationwide observational cohort study recruiting patients from 53 centers across the United Kingdom before the initiation of biologic treatment and following them up prospectively for 12 months. Three hundred forty-two patients starting either abatacept or adali

SUBMITTER: Yap CF 

PROVIDER: S-EPMC12854005 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature